— Know what they know.
Not Investment Advice

CTNM NASDAQ

Contineum Therapeutics, Inc.
1W: +9.4% 1M: -35.2% 3M: -42.5% YTD: -28.5% 1Y: -26.8%
$9.00
+0.86 (+10.57%)
After Hours: $9.10 (+0.10, +1.11%)
Weekly Expected Move ±23.0%
$4 $6 $8 $10 $12
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 26 · $268.3M mcap · 28M float · 2.54% daily turnover · Short 69% of daily vol
Credit Risk of going bust: higher than 50% of companies Debt: 2.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.03 (down 99.6%), Contineum Therapeutics, Inc. would be worth roughly what it owes.
Total debt $6.6M against a stock market value of $268.3M.
Distance to default 5.09 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.3M (short-term plus half of long-term), stock volatility 82.1%; Altman Z'' 25.32. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
32.1 / 100
NoneWeakNarrowWide
Primary source: Network Effects  ·  ROIC: -541.6%
Cost Advantage
33
Intangibles
25
Switching Cost
38
Network Effect
43
Scale
22
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. CTNM has No discernible competitive edge (32.1/100). The business operates without significant structural advantages. The primary source of advantage is Network Effects. Negative ROIC of -541.6% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$17
Low
$21
Avg Target
$28
High
Based on 3 analysts since Jul 30, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 2Hold: 2Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$21.33
Analysts3
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-09-30 Stifel Nicolaus Paul Matteis $29 $28 -1 +116.7% $12.92
2026-09-27 Morgan Stanley Sean Laaman $16 $17 +1 +35.4% $12.56
2026-09-15 Robert W. Baird — $14 $19 +5 +28.2% $14.82
2026-05-14 Morgan Stanley — $14 $16 +2 +13.1% $14.15
2026-01-08 Morgan Stanley — Initiated $14 — +46.4% $9.56
2025-11-24 Robert W. Baird — $16 $14 -2 +27.9% $10.95
2025-11-21 RBC Capital Brian Abrahams $30 $22 -8 +80.0% $12.22
2025-09-25 Leerink Partners — Initiated $20 — +84.2% $10.86
2025-03-07 Robert W. Baird — $32 $16 -16 +136.3% $6.77
2024-10-21 Robert W. Baird Joel Beatty Initiated $32 — +99.1% $16.07
2024-04-30 RBC Capital Brian Abrahams Initiated $30 — +87.5% $16.00
2024-04-29 Stifel Nicolaus Paul Matteis Initiated $29 — +81.2% $16.00

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C+
Oct 27, 2026
DCF
3
ROE
1
ROA
1
D/E
4
P/E
1
P/B
3
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. CTNM receives an overall rating of C+. Strongest factors: D/E (4/5). Areas of concern: ROE (1/5), ROA (1/5), P/E (1/5).
Rating Change History
DateFromTo
2026-10-12 C C+
2026-10-01 C+ C
2026-04-01 B- C+
2026-03-16 C+ B-
2026-03-12 B- C+
2026-03-10 C+ B-
2026-03-09 C C+
2026-03-06 C+ C

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ — Grade A+
Profitability
—
Balance Sheet
85
Earnings Quality
66
Growth
—
Value
38
Momentum
—
Safety
100
Cash Flow
—

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
33.57
Safe Zone
Piotroski F-Score
4/9
✗ ✗ ✓ ✓ ✓ ✓ ✗ ✗ ✗
Beneish M-Score
—
—
Ohlson O-Score
-0.39
Bankruptcy prob: 40.5%
Moderate
Credit Rating
A+
Score: 75.6/100
Trend: Deteriorating
Earnings Quality
—
OCF/NI: 0.92x
Accruals: -2.1%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. CTNM scores 33.57, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. CTNM scores 4/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. CTNM's implied 40.5% bankruptcy probability is elevated and warrants attention to the balance sheet. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. CTNM receives an estimated rating of A+ (score: 75.6/100), with a deteriorating trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-4.75x
PEG
-0.20x
P/S
0.00x
P/B
1.28x
P/FCF
-11.49x
P/OCF
—
EV/EBITDA
-6.21x
EV/Revenue
—
EV/EBIT
-6.17x
EV/FCF
-7.18x
Earnings Yield
-9.37%
FCF Yield
-8.71%
Shareholder Yield
0.00%
Graham Number
—
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. CTNM currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.000
NI / EBT
×
Interest Burden
0.924
EBT / EBIT
×
EBIT Margin
—
EBIT / Rev
×
Asset Turnover
0.000
Rev / Assets
×
Equity Multiplier
1.054
Assets / Equity
=
ROE
-28.0%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. CTNM's ROE of -28.0% is driven by A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
—
Price/Value
—
Margin of Safety
—
Premium
—

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 642 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$8.14
Median 1Y
$4.43
5th Pctile
$1.04
95th Pctile
$19.17
Ann. Volatility
84.6%
Analyst Target
$21.33
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Carmine N. Stengone
President and Chief Executive Officer
$655,620 $— $3,409,448
Timothy R. Watkins,
M.D., MSc. Chief Medical Officer and Head of Development
$359,501 $— $1,763,323
Peter T. Slover
Chief Financial Officer
$487,487 $— $1,577,903

CEO Pay Ratio

11:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $3,409,448
Avg Employee Cost (SGA/emp): $324,255
Employees: 51

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
51
+24.4% YoY
Revenue / Employee
—
Profit / Employee
$-1,176,039
NI: $-59,978,000
SGA / Employee
$324,255
Avg labor cost proxy
R&D / Employee
$1,010,235
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
ROE -4.1% -9.2% -17.1% -27.0% -29.2% -30.4% -26.1% -26.9% -28.0% -28.01%
ROA -4.1% -8.9% -15.9% -25.1% -28.1% -29.2% -24.5% -25.4% -26.6% -26.57%
ROIC 15.6% 6.2% -110.5% 562.4% 17.1% 7.5% -8.5% -5.0% -5.4% -5.42%
ROCE -4.1% -9.2% -16.7% -27.4% -33.6% -33.3% -23.3% -23.9% -25.5% -25.54%
Gross Margin — — — — — — — — — —
Operating Margin — — — — — — — — — —
Net Margin — — — — — — — — — —
EBITDA Margin — — — — — — — — — —
FCF Margin — — — — — — — — — —
OCF Margin — — — — — — — — — —
ROE 3Y Avg snapshot only -20.45%
ROA 3Y Avg snapshot only -19.38%
ROIC Economic snapshot only -21.30%
Cash ROA snapshot only -21.17%
Cash ROIC snapshot only -5.47%
CROIC snapshot only -5.52%
Valuation
Metric Trend Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
P/E Ratio -50.28 -25.55 -11.19 -3.62 -1.81 -5.56 -5.88 -8.34 -10.67 -4.745
P/S Ratio — — — — — — — — — 0.000
P/B Ratio 2.08 2.34 1.91 0.98 0.60 1.83 1.35 1.95 2.56 1.283
P/FCF -53.43 -33.44 -15.09 -4.56 -2.20 -6.25 -6.35 -8.46 -11.49 -11.486
P/OCF — — — — — — — — — —
EV/EBITDA -26.25 -14.58 -5.36 0.08 1.14 -2.51 -1.59 -4.10 -6.21 -6.206
EV/Revenue — — — — — — — — — —
EV/EBIT -26.08 -14.48 -5.33 0.08 1.13 -2.49 -1.58 -4.08 -6.17 -6.168
EV/FCF -27.71 -18.95 -7.18 0.10 1.43 -2.90 -1.77 -4.31 -7.18 -7.185
Earnings Yield -2.0% -3.9% -8.9% -27.6% -55.3% -18.0% -17.0% -12.0% -9.4% -9.37%
FCF Yield -1.9% -3.0% -6.6% -21.9% -45.5% -16.0% -15.7% -11.8% -8.7% -8.71%
Price/Tangible Book snapshot only 2.562
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Current Ratio 58.92 37.06 20.69 21.47 24.51 29.07 27.50 38.00 37.17 37.171
Quick Ratio 58.92 37.06 20.69 21.47 24.51 29.07 27.50 38.00 37.17 37.171
Debt/Equity 0.00 0.00 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.027
Net Debt/Equity -1.00 -1.01 -1.00 -1.00 -0.99 -0.98 -0.98 -0.96 -0.96 -0.960
Debt/Assets 0.00 0.00 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.026
Debt/EBITDA -0.07 -0.03 -0.19 -0.12 -0.10 -0.09 -0.13 -0.11 -0.11 -0.106
Net Debt/EBITDA 24.37 11.14 5.90 3.57 2.89 2.89 4.12 3.95 3.72 3.715
Interest Coverage — — — — — — — — — —
Equity Multiplier 1.02 1.03 1.07 1.07 1.07 1.06 1.06 1.05 1.04 1.045
Cash Ratio snapshot only 36.247
Cash to Debt snapshot only 35.983
FCF to Debt snapshot only -8.133
Defensive Interval snapshot only 1302.3 days
Efficiency & Turnover
Metric Trend Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Asset Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Inventory Turnover — — — — — — — — — —
Receivables Turnover — — — — — — — — — —
Payables Turnover 0.00 0.00 0.00 0.00 0.06 0.15 0.11 0.06 0.06 0.065
DSO — — — — — — — — — —
DIO — — — — 0 0 0 0 0 0.0 days
DPO — — — — 6318 2490 3225 5863 5646 5646.2 days
Cash Conversion Cycle — — — — — — — — — —
Fixed Asset Turnover snapshot only 0.000
Cash Velocity snapshot only 0.000
Growth (YoY)
Metric Trend Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue — — — — — — — — — —
Net Income — — — — -5.3% -2.1% -77.2% -17.3% -1.2% -1.22%
EPS — — — — -5.3% -1.8% -48.5% 18.7% 30.0% 30.04%
FCF — — — — -4.5% -2.6% -1.2% -45.8% -14.3% -14.28%
EBITDA — — — — -5.6% -2.2% -83.6% -17.2% -5.5% -5.47%
Op. Income — — — — 4.3% 2.4% -2.1% -2.6% -2.9% -2.86%
OCF Growth snapshot only -14.13%
Asset Growth snapshot only 36.90%
Equity Growth snapshot only 39.83%
Debt Growth snapshot only 14.33%
Shares Change snapshot only 44.69%
Growth Quality
Metric Trend Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue Stability — — — — — — — — 1.00 1.000
Earnings Stability — — — — — — — — 0.76 0.761
Margin Stability — — — — — — — — — —
Rev. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0
Earnings Persistence — — — — — — — — 1.00 0.995
Earnings Smoothness — — — — — — — — — —
ROE Trend — — — — — — — — -0.05 -0.054
Gross Margin Trend — — — — — — — — — —
FCF Margin Trend — — — — — — — — — —
Sustainable Growth Rate — — — — — — — — — —
Internal Growth Rate — — — — — — — — — —
Cash Flow Quality
Metric Trend Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
OCF/Net Income 0.93 0.75 0.73 0.79 0.82 0.88 0.92 0.98 0.92 0.921
FCF/OCF 1.01 1.01 1.01 1.01 1.01 1.01 1.00 1.01 1.01 1.009
FCF/Net Income snapshot only 0.929
CapEx/Revenue — — — — — — — — — —
CapEx/Depreciation snapshot only 1.196
Accruals Ratio -0.00 -0.02 -0.04 -0.05 -0.05 -0.03 -0.02 -0.01 -0.02 -0.021
Sloan Accruals snapshot only 0.305
Cash Flow Adequacy snapshot only -115.734
Dividends & Buybacks
Metric Trend Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio — — — — — — — — — —
FCF Payout Ratio — — — — — — — — — —
Total Payout Ratio — — — — — — — — — —
Div. Increase Streak — — — — — — — — — —
Chowder Number — — — — — — — — — —
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -23.9% -22.0% -28.7% -60.3% -0.9% -6.0% -31.9% -23.1% -18.5% -18.51%
Total Shareholder Return -23.9% -22.0% -28.7% -60.3% -0.9% -6.0% -31.9% -23.1% -18.5% -18.51%
DuPont Factors
Metric Trend Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Tax Burden (NI/EBT) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Interest Burden (EBT/EBIT) 1.00 1.00 1.00 0.96 0.96 0.97 0.97 0.96 0.92 0.924
EBIT Margin — — — — — — — — — —
Asset Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Equity Multiplier 1.02 1.03 1.07 1.07 1.04 1.04 1.07 1.06 1.05 1.054
Per Share
Metric Trend Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
EPS (Diluted TTM) $-0.35 $-0.75 $-1.31 $-1.93 $-2.20 $-2.11 $-1.94 $-1.57 $-1.54 $-1.54
Book Value/Share $8.46 $8.17 $7.66 $7.14 $6.62 $6.42 $8.46 $6.70 $6.40 $6.40
Tangible Book/Share $8.46 $8.17 $7.66 $7.14 $6.62 $6.42 $8.46 $6.70 $6.40 $6.40
Revenue/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
FCF/Share $-0.33 $-0.57 $-0.97 $-1.53 $-1.81 $-1.88 $-1.80 $-1.54 $-1.43 $-1.43
OCF/Share $-0.32 $-0.56 $-0.96 $-1.51 $-1.79 $-1.87 $-1.79 $-1.53 $-1.41 $-1.41
Cash/Share $8.50 $8.31 $7.92 $7.37 $6.78 $6.49 $8.52 $6.60 $6.31 $6.31
EBITDA/Share $-0.35 $-0.74 $-1.30 $-2.00 $-2.27 $-2.18 $-2.00 $-1.62 $-1.65 $-1.65
Debt/Share $0.02 $0.02 $0.24 $0.23 $0.22 $0.20 $0.27 $0.19 $0.18 $0.18
Net Debt/Share $-8.48 $-8.29 $-7.68 $-7.14 $-6.55 $-6.29 $-8.25 $-6.41 $-6.14 $-6.14
Academic Models
Metric Trend Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Altman Z-Score — — — — — — — — — 33.566
Altman Z-Prime snapshot only 62.041
Piotroski F-Score 2 2 2 2 1 1 2 3 4 4
Beneish M-Score — — — — — — — — — —
Ohlson O-Score snapshot only -0.386
ROIC (Greenblatt) snapshot only -25.58%
Net-Net WC snapshot only $6.19
EVA snapshot only $-53407710.00
Credit
Metric Trend Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Credit Rating snapshot only A+
Credit Score 76.30 76.10 87.91 87.78 87.75 87.62 75.72 75.73 75.58 75.581
Credit Grade snapshot only 5
Credit Trend snapshot only -12.167
Implied Spread (bps) snapshot only 125.000
Industry Credit Rank snapshot only 76
Sector Credit Rank snapshot only 70

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms